<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706611</url>
  </required_header>
  <id_info>
    <org_study_id>B-2019-041-01</org_study_id>
    <nct_id>NCT04706611</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fecal Microbiota Transplantation</brief_title>
  <acronym>FMT</acronym>
  <official_title>Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Intestinal Dysbiosis -A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou First People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, researches illustrate that multifactorial diseases such as functional&#xD;
      gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological&#xD;
      diseases are associated with an abnormal microbiome structure-dysbiosis, which means the&#xD;
      imbalance of the microbiome community. Fecal microbiota transplantation (FMT), the infusion&#xD;
      of faeces from a healthy donor to the gastrointestinal tract of a recipient patient aiming to&#xD;
      alter the intestine microbiota, is recommended to be performed in Clostridium difficile&#xD;
      infection(CDI) as the most effective therapy. It also being used experimentally in the&#xD;
      treatment of the disease states linked to dysbiosis of the intestinal microbiota. However,&#xD;
      the efficacy and safety of FMT to treat the dysbiosis-associated diseases is still in its&#xD;
      infancy. To further verify the indications above, more data is required to be collected&#xD;
      through studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of FMT in patients with gastrointestinal symptom will be assessed by the change of Gastrointestinal Symptom Rating Scale(GSRS).</measure>
    <time_frame>1 year</time_frame>
    <description>Gastrointestinal Symptom Rating Scale(GSRS) is a measure of gastrointestinal symptom severity in five clusters (pain, bloating, constipation, diarrhea, and early satiety).The items are scored between 1 and 7, where 1 corresponds to &quot;no discomfort at all&quot; and 7 to &quot;very severe discomfort&quot; from the symptom. The participants will be asked to filled in the scale in several time points from baseline to 12 months after FMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events(CTCAE) V4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Numbers of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome)</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>40</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Fecal Microbiota Transplantation</condition>
  <arm_group>
    <arm_group_label>Irritable Bowel Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Constipation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clostridium Difficile Infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Dyspepsia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metabolic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Alcoholic Fatty Liver Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autism Spectrum Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Enteritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Allergic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Graft-versus-Host Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obesity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes mellitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-Drug Resistant Infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Encephalopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteric Dysbacteriosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudomembranous Enteritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Pancreatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Fatigue Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute-on-chronic Liver Failure with HBV Infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcoholic Liver Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anorexia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decompensated Cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Henoch-Schonlein Purpura</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune Liver Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgG4-Related Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein-losing Enteropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asperger Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ankylosing spondylitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune checkpoint inhibition-related colitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune enteropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-induced diarrhea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal Microbiota Transplantation will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Procedure: Fecal Microbiota Transplantation</description>
    <arm_group_label>Acute Pancreatitis</arm_group_label>
    <arm_group_label>Acute-on-chronic Liver Failure with HBV Infection</arm_group_label>
    <arm_group_label>Alcoholic Liver Disease</arm_group_label>
    <arm_group_label>Ankylosing spondylitis</arm_group_label>
    <arm_group_label>Anorexia</arm_group_label>
    <arm_group_label>Asperger Syndrome</arm_group_label>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
    <arm_group_label>Autism Spectrum Disorder</arm_group_label>
    <arm_group_label>Autoimmune Liver Disease</arm_group_label>
    <arm_group_label>Autoimmune enteropathy</arm_group_label>
    <arm_group_label>Celiac Disease</arm_group_label>
    <arm_group_label>Chronic Fatigue Syndrome</arm_group_label>
    <arm_group_label>Clostridium Difficile Infection</arm_group_label>
    <arm_group_label>Constipation</arm_group_label>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_label>Decompensated Cirrhosis</arm_group_label>
    <arm_group_label>Diabetes mellitus</arm_group_label>
    <arm_group_label>Drug-induced diarrhea</arm_group_label>
    <arm_group_label>Enteric Dysbacteriosis</arm_group_label>
    <arm_group_label>Food Allergic</arm_group_label>
    <arm_group_label>Functional Dyspepsia</arm_group_label>
    <arm_group_label>Graft-versus-Host Disease</arm_group_label>
    <arm_group_label>Henoch-Schonlein Purpura</arm_group_label>
    <arm_group_label>Hepatic Encephalopathy</arm_group_label>
    <arm_group_label>IgG4-Related Disease</arm_group_label>
    <arm_group_label>Immune checkpoint inhibition-related colitis</arm_group_label>
    <arm_group_label>Irritable Bowel Syndrome</arm_group_label>
    <arm_group_label>Metabolic Syndrome</arm_group_label>
    <arm_group_label>Multi-Drug Resistant Infection</arm_group_label>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <arm_group_label>Non-Alcoholic Fatty Liver Disease</arm_group_label>
    <arm_group_label>Obesity</arm_group_label>
    <arm_group_label>Parkinson's Disease</arm_group_label>
    <arm_group_label>Protein-losing Enteropathy</arm_group_label>
    <arm_group_label>Pseudomembranous Enteritis</arm_group_label>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_label>Radiation Enteritis</arm_group_label>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_label>Ulcerative colitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Confirmed diagnosis of any of following diseases:&#xD;
&#xD;
          -  Irritable Bowel Syndrome&#xD;
&#xD;
          -  Ulcerative colitis&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Constipation&#xD;
&#xD;
          -  Clostridium Difficile Infection&#xD;
&#xD;
          -  Functional Dyspepsia&#xD;
&#xD;
          -  Parkinson's Disease&#xD;
&#xD;
          -  Metabolic Syndrome&#xD;
&#xD;
          -  Non-Alcoholic Fatty Liver Disease&#xD;
&#xD;
          -  Autism Spectrum Disorder&#xD;
&#xD;
          -  Radiation Enteritis&#xD;
&#xD;
          -  Atopic Dermatitis&#xD;
&#xD;
          -  Food Allergic&#xD;
&#xD;
          -  Graft-versus-Host Disease&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Multi-Drug Resistant Infection&#xD;
&#xD;
          -  Hepatic Encephalopathy&#xD;
&#xD;
          -  Enteric Dysbacteriosis&#xD;
&#xD;
          -  Multiple Sclerosis&#xD;
&#xD;
          -  Pseudomembranous Enteritis&#xD;
&#xD;
          -  Acute Pancreatitis&#xD;
&#xD;
          -  Chronic Fatigue Syndrome&#xD;
&#xD;
          -  Acute-on-chronic Liver Failure with HBV Infection&#xD;
&#xD;
          -  Alcoholic Liver Disease&#xD;
&#xD;
          -  Anorexia&#xD;
&#xD;
          -  Decompensated Cirrhosis&#xD;
&#xD;
          -  Henoch-Schonlein Purpura&#xD;
&#xD;
          -  Autoimmune Liver Disease&#xD;
&#xD;
          -  Systemic Lupus Erythematosus&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  IgG4-Related Disease&#xD;
&#xD;
          -  Celiac Disease&#xD;
&#xD;
          -  Protein-losing Enteropathy&#xD;
&#xD;
          -  Asperger Syndrome&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Ankylosing spondylitis&#xD;
&#xD;
          -  Immune checkpoint inhibition-related colitis&#xD;
&#xD;
          -  Autoimmune enteropathy&#xD;
&#xD;
          -  Drug-induced diarrhea&#xD;
&#xD;
          -  Suffering from gastrointestinal symptoms such as constipation, diarrheas, abdominal&#xD;
             pain, flatulence, etc.&#xD;
&#xD;
          -  The participants must be able to tolerate the FMT infusion method such as endoscopy,&#xD;
             colonoscopy, capsule, nasoduodenal tube insertion, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy or breast-feeding;&#xD;
&#xD;
          -  Suffering from other severe diseases, including liver or kidney failure, heart&#xD;
             failure, MODS, coma, cerebrovascular accident;&#xD;
&#xD;
          -  Known contraindication to all FMT infusion method such as nasoduodenal tube insertion,&#xD;
             endoscopy, colonoscopy and enema;&#xD;
&#xD;
          -  Any conditions that may render the efficacy of FMT or at the discretion of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongli Huang, MM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou First People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongjian Zhou, MM</last_name>
    <phone>86-13503060150</phone>
    <email>eyzhouyongjian@scut.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongli Huang, MM</last_name>
    <phone>86-13631316718</phone>
    <email>honglisums@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjian Zhou, MM</last_name>
      <phone>86-13503060150</phone>
      <email>eyzhouyongjian@scut.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hongli Huang, MM</last_name>
      <phone>86-13631316718</phone>
      <email>honglisums@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yandi Liu, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017 Apr;17(4):219-232. doi: 10.1038/nri.2017.7. Epub 2017 Mar 6. Review.</citation>
    <PMID>28260787</PMID>
  </reference>
  <reference>
    <citation>Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013 Feb;108(2):177-85. doi: 10.1038/ajg.2012.450. Epub 2013 Jan 15. Review.</citation>
    <PMID>23318479</PMID>
  </reference>
  <reference>
    <citation>Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4. Epub 2017 Feb 15.</citation>
    <PMID>28214091</PMID>
  </reference>
  <reference>
    <citation>Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med. 2019 Jan 27;70:335-351. doi: 10.1146/annurev-med-111717-122956. Epub 2018 Nov 7. Review.</citation>
    <PMID>30403550</PMID>
  </reference>
  <reference>
    <citation>Lee P, Yacyshyn BR, Yacyshyn MB. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes Obes Metab. 2019 Mar;21(3):479-490. doi: 10.1111/dom.13561. Epub 2018 Nov 20. Review.</citation>
    <PMID>30328245</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017 Dec;66(6):1727-1738. doi: 10.1002/hep.29306. Epub 2017 Oct 30.</citation>
    <PMID>28586116</PMID>
  </reference>
  <reference>
    <citation>Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, Cui C, Shen YQ. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018 May;70:48-60. doi: 10.1016/j.bbi.2018.02.005. Epub 2018 Feb 20.</citation>
    <PMID>29471030</PMID>
  </reference>
  <reference>
    <citation>Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):17-24. doi: 10.1016/S2468-1253(17)30338-2. Epub 2017 Nov 1.</citation>
    <PMID>29100842</PMID>
  </reference>
  <reference>
    <citation>El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020 May;69(5):859-867. doi: 10.1136/gutjnl-2019-319630. Epub 2019 Dec 18.</citation>
    <PMID>31852769</PMID>
  </reference>
  <reference>
    <citation>Leshem A, Horesh N, Elinav E. Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome. Front Immunol. 2019 Jun 14;10:1341. doi: 10.3389/fimmu.2019.01341. eCollection 2019. Review.</citation>
    <PMID>31258528</PMID>
  </reference>
  <reference>
    <citation>DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30.</citation>
    <PMID>31665575</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

